Ambrx Biopharma Inc

Ambrx Biopharma Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ambrx Biopharma, Inc. is a clinical-stage biologics company, which engages in discovering and developing a novel class of engineered precision biologics (EPBs). Using its proprietary expanded genetic code technology platform, it allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, and ARX305. The company was founded on August 11, 2023 and is headquartered in La Jolla, CA.

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction.

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

Kaman Corporation

Super Micro Computer

With stocks up 200%, you face a dilemma. While you don't want to fight momentum, you also don't want to buy into excessive exuberance and jump into a stock at its top, forced to hold until break-even or sell for a loss down the road.

3 Stocks to Buy That Are Up 200% or More in 2024

Here is how Ambrx Biopharma Inc. (AMAM) and HealthEquity (HQY) have performed compared to their sector so far this year.

Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?

Johnson & Johnson

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopharma, Inc. (NasdaqGS: AMAM) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Ambrx will receive $28.00 in cash for each share of Ambrx that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

J&J (JNJ) is set to acquire Ambrx Biopharma (AMAM) in an all-cash transaction for $2.0 billion. The transaction will likely close in first-half 2024.

Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J

Shares of engineered therapeutics specialist Ambrx Biopharma (NASDAQ: AMAM ) skyrocketed on Monday following a major announcement. Pharmaceutical and medical technology stalwart Johnson & Johnson (NYSE: JNJ ) will buy out the company, which should strengthen its oncology unit.

Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?

The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.

J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion

Shares of Ambrx Biopharma Inc (NASDAQ: AMAM) roughly doubled this morning after Johnson & Johnson (NYSE: JNJ) revealed plans of acquiring the clinical-stage biopharmaceutical company. Details of the JNJ-Ambrx deal Johnson & Johnson is willing to pay about $2.0 billion to buy the Nasdaq-listed firm.

Ambrx Biopharma stock doubles on JNJ deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Ambrx Biopharma, Inc. (NASDAQ: AMAM) to Johnson & Johnson for $28.00 per share in cash is fair to Ambrx shareholders. Halper Sadeh encourages Ambrx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Ambrx and.

AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholders

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx's closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion.

Ambrx Announces Sale to Johnson & Johnson

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired.

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

American Coastal Insurance Corp

Coinbase

Soleno Therapeutics

In recent years, most reports of assets surging by thousands of percents in relatively short periods come from the crypto market, where various cryptocurrencies – especially smaller altcoins and meme coins – can very quickly make staggering surges.

The underdogs of 2023: Small-cap stocks that made it big

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023.

Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)

Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose Cohort 8 The cohort (2.88 mg/kg) is now fully enrolled with 20 patients Recommended phase 2 dose expected by early next year SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate (ADC) ARX517 in the ongoing APEX-01 Phase 1 / 2 dose escalation and dose expansion clinical trial in metastatic castration-resistant prostate cancer (mCRPC). Following the completion of the 21-day DLT observation period from APEX-01 dose escalation Cohort 9 (3.4 mg/kg), no DLTs or SAEs were observed.

Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology for next-generation ADCs has shown safety benefits and potential efficacy, making it an attractive acquisition candidate. ARX788, an ADC candidate for metastatic breast cancer, alone has the potential to drive a significant upside for Ambrx stock.

Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data

Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with cohorts 6 through 8. In order to see if ARX517 can be improved upon for these patients with mCRPC, expansion of cohort 8 is underway and then dose escalation of cohort 9 was initiated. The global prostate cancer market size is expected to reach $27.51 billion by 2032; 10% to 50% of prostate cancer cases progress to the metastatic castration-resistant state of disease.

Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data

Newly published data from the Phase 1 portion of the on-goingPhase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoints demonstrate consistent and promising anti-cancer activity at therapeutic doses of 2.0 – 2.88 mg/kg (Cohorts 6-8) in heavily pretreated patients (median of 4 and maximum of 13 prior lines of therapy): 52% (12/23) of patients experienced a ≥50% PSA reduction 81% (17/21) of patients experienced ≥50% circulating tumor DNA reduction 50% (3/6) of patients with prior PSMA-targeted radionuclide therapy (TRT) experienced a ≥50% PSA reduction 50% (2/4) experienced a >30% reduction in target lesion(s) A strong and highly differentiated safety profile observed across 65 patients at all dose levels with no treatment-related SAEs or DLTs SAN DIEGO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that in biomarker unselected patients ARX517 monotherapy demonstrated a strong antibody-drug conjugate (ADC) safety profile at all doses tested with promising early efficacy signals that included PSA50 declines, ctDNA reductions, and RECIST v1.1 tumor response. The ESMO clinical posters present updated safety, efficacy and PK data from Ambrx's on-going trial, APEX-01 (NCT04662580).

Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments

Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6 (2.0 mg/kg), 2 of 3 in Cohort 7 (2.4 mg/kg) and 2 of 3 in Cohort 8 (2.88 mg/kg) No drug-related severe adverse events (SAEs) and no dose limiting toxicities (DLTs) observed in any cohort Pharmacokinetic (PK) data indicated strong ADC stability preventing premature release of anticancer payload Ambrx to host a live event / webcast to discuss additional data presented at ESMO on Sunday, October 22, 2023, at 8 p.m. CEST / 2 p.m.

Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress

In-person event and virtual webcast to be held on Sunday, October 22, 2023 at 8:00pm CEST / 2:00pm ET In-person event and virtual webcast to be held on Sunday, October 22, 2023 at 8:00pm CEST / 2:00pm ET

Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023

The company, formerly based in the Cayman Islands, is moving to Delaware. It is expected to announce trial data next week regarding two of its lead therapies.

Why Shares of Ambrx Biopharma Soared This Week

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview and participate in one-on-one meetings at the Baird Global Healthcare Conference and the Morgan Stanley 21st Annual Global Healthcare Conference, both being held in New York, NY. The presentations will focus on the status of Ambrx's lead clinical candidates, ARX788 and ARX517.

Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences

Ambrx is no longer flying under the radar. Instead, AMAM stock has soared 483% this year as enthusiasm grows for its cancer smart bombs.

Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.

Here is how Ambrx Biopharma Inc. Sponsored ADR (AMAM) and Sientra (SIEN) have performed compared to their sector so far this year.

Is Ambrx Biopharma (AMAM) Outperforming Other Medical Stocks This Year?

Ambrx Biopharma is a clinical-stage biotech company developing precision biologics for cancer treatment. They have a strong financial position with $235.1 million in liquid assets and a cash runway of approximately four years. Their leading candidates, ARX788 and ARX517, show promising results in clinical trials for breast cancer and prostate cancer, respectively.

Promising Developments In Ambrx's Engineered Precision Biologics

Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meeting Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meeting

News for Ambrx Biopharma Inc Stock (AMAM)